[{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Relay Therapeutics \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals for Atirmociclib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.

                          Brand Name : RLY-2608

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank